טוען...
Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
BACKGROUND: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A national expert...
שמור ב:
| הוצא לאור ב: | BMC Med Ethics |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094497/ https://ncbi.nlm.nih.gov/pubmed/33947377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12910-021-00623-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|